NCT06890286View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

January 3, 2025

Study Completion Date

January 3, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

BR3006

One tablet administered alone

DRUG

BR3006A

One tablet administered alone

DRUG

BR3006B

One tablet administered alone

DRUG

BR3006C

One tablet administered alone

Trial Locations (1)

Unknown

Clinical Research Center, H PLUS Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY